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Background: Familial Mediterranean fever (FMF) is an autosomal recessive disease characterized by self-limiting
recurrent attacks of fever and serosal inflammation, leading to abdominal, thoracic or articular pain.
Objective: To detect variable clinical presentations and genotypic distribution of different groups of FMF patients
and the efficacy of colchicine therapy in treatment of these groups of FMF after one year.
Methods: A cross-sectional study was conducted on 70 patients already diagnosed with FMF and following-up at
the Rheumatology Clinic, Children's Hospital - Cairo University. Diagnosis of FMF was determined according to Tel
Hashomer criteria for FMF. All patients were subjected to a questionnaire including detailed history with emphasis
on clinical manifestations and colchicine dose to control attacks. Mutational analysis was performed for all study
subjects covering 12 mutations in the MEFV gene: E148Q, P369S, F479L, M680I (G/C), M680I (G/A), I692del, M694V,
M694I, K695R, V726A, A744S and R761H. Response to colchicine treatment was evaluated as complete, incomplete
and unresponsive.
Results: Out of the 70 patients- 40 males and 30 females- fever was the most common presenting feature,
followed by abdominal pain, and arthritis; documented in 95.7%, 94.3%, and 77.1% of cases respectively. Mutational
analysis detected gene mutation on both alleles in 20 patients (homozygotes), on only 1 allele in 40 patients
(heterozygotes), and on none of the alleles (uncharacterized cases). Mild to moderate disease severity score
(according to Tel Hashomer key to severity score) was detected in a significant proportion of heterozygotes and
the uncharacterized group than the homozygotes. All patients received colchicine therapy; 22.9% of them showed
complete response, 74.3% showed incomplete response and 2.9% showed no response to therapy. The colchicine
dose needed to control attacks was significantly lower in heterozygotes than the homozygotes(P=0.04). Also
patients’ response to colchicine therapy was significantly better in the heterozygous group(P=0.023).
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Conclusion: Fever, abdominal pain and arthritis are the most common presenting features for homozygous,
Heterozygous and uncharacterized patients. E148Q, V726A, and M680I were the most common mutations detected
in the heterozygous group. Homozygosity were found for M680I, M694V, and M694I mutations in 13 patients (65%
of homozygotes). Heterozygotes presenting with severe phenotype should be further analyzed for less common
second MEFV mutation using gene sequencing. The colchicine dose required to control the attacks was
significantly lower and patients’ response to colchicine therapy was significantly better in the heterozygous group
than homozygous group.
Keywords: Familial Mediterranean fever, Clinical presentations, Efficacy, ColchicineIntroduction
FMF is an autosomal recessive disease characterized by
self-limiting recurrent attacks of fever and serosal in-
flammation, leading to abdominal, thoracic or articular
pain. Erysipelas-like skin lesions and diffuse myalgia are
less frequent manifestations [1]. The disease course can
be complicated by development of amyloid deposition
and organ failure which can be fatal [2].
The frequency of FMF in any location depends on the
ethnic background of the population. Specific ethnic
groups have an increased prevalence [3]. The disease is
most prevalent among non-Ashkenazi Jews, Arabs,
Turks and Armenians with carrier frequencies of 1:5 to
1:16, 1:5, 1:5, and 1:7, respectively [4].
The diagnosis of FMF has been based before on the
clinical features and exclusion of other causes of periodic
fever, thus making it difficult to establish a correct diag-
nosis in patients with milder or atypical manifestations
of the disease [5].
Evidences accumulating suggest that the clinical
spectrum of FMF associated with MEFV mutations
extends from the typical manifestation of the full blown
disease to the asymptomatic state, this make the mo-
lecular analysis of MEFV a useful tool in the clinical
practice [6]. In the clinical context of FMF, the presence
of two mutations on different alleles (homozygousity or
compound heterozygousity) makes it possible to confirm
the diagnosis of FMF but when only one mutation is
present, the diagnosis is not ascertained, but neither can
it be excluded [7].
The goals of therapy are to reduce morbidity and
to prevent complications of the disease. Treatment of
FMF at this point consists of taking colchicine, a
neutrophil-suppressive agent. Colchicine is so effective
in preventing attacks of FMF and the development of
amyloidosis that the most important aspect of medical
care is to make the correct diagnosis and to institute
therapy [8].
This study aimed to detect variable clinical presenta-
tions and genotypic distribution of FMF patients and the
efficacy of colchicine therapy in treatment of these
groups of FMF after one year.Methods
A cross-sectional study was conducted on 70 patients
with FMF during the period from January, 2011 to July,
2011. The diagnosis of FMF was determined according
to Tel Hashomer criteria for FMF shown in Table 1.
The Scientific Research Committee of Pediatrics De-
partment, Faculty of Medicine-Cairo University,
approved the study design. All data were confidential for
the research use only.
Patients fulfilled the criteria of being diagnosed with
FMF for more than one year and were followed up and
adherent to treatment in the Rheumatology clinic, Chil-
dren's Hospital, Cairo University for more than one year
and those diagnosed for less than one year and non-
compliant patients either to therapy or to follow up vis-
its were excluded.
All patients were subjected to a questionnaire contain-
ing detailed history, demographic status (gender, age of
onset, age of diagnosis, time interval between disease
onset and diagnosis, duration of follow-up, number of
attacks per year before and after colchicine treatment,
consanguinity, family history of FMF, diseases that may
be associated with FMF, colchicine dosage to control
attacks, clinical manifestations (fever, abdominal pain,
arthritis, chest pain, and erysipelas-like erythema), his-
tory of other diseases and development of amyloidosis,
presence of a family history of FMF, amyloidosis and a
treatment regimen was developed. Then, Response to
colchicine treatment was evaluated as complete (attack
free), incomplete (decline >50% in the frequency of
attacks) and unresponsive.
According to clinical condition, the severity score of
the disease was calculated based on the Tel Hashomer
Severity Score shown in Table 2.
Mutation analysis
The FMF gene mutations were tested using the FMF
Strip AssayTM, ViennaLab Labordiagnostika GmbH, Vi-
enna, Austria. The assay is based on polymerase chain
reaction (PCR) and reverse hybridization and includes
three successive steps: (1) DNA isolation from anticoa-
gulated blood, (2) PCR ampliWcation using biotinylated
Table 1 Tel Hashomer criteria for familial Mediterranean fever [1]
Major criteria Minor criteria
• Recurrent febrile episodes accompanied by serositis • Recurrent febrile episodes
• Amyloidosis of AA-type without a predisposing disease • Erysipelas-like erythema
• Favorable response to continuous colchicine treatment • Familial Mediterranean fever in a first-degree relative
*If 2 major Tel Hashomer criteria or one major criterion and two minor ones are satisfied the diagnosis of FMF can be confirmed; if only one major and one minor
criteria are satisfied the diagnosis is only probable.
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test strip containing both wild and mutant allele-specific
oligonucleotide probes immobilized as an array of paral-
lel lines. Bound biotinylated sequences were detected
using streptavidin–alkaline phosphatase and color sub-
strates. The assay covers 12 mutations in the MEFV
gene: E148Q, P369S, F479L, M680I (G/C), M680I (G/A),
I692del, M694V, M694I, K695R, V726A, A744S and
R761H [10].
For each polymorphic position, one of three possible
staining patterns were obtained either wild type probe
only (normal genotype), wild type and mutant probe
(heterozygous genotype or carrier) or mutant probe only
(homozygous mutant genotype or affected). Records of
patients were classified into three groups according to
the presence of gene mutation on both of the alleles
(homozygotes), on only 1 allele (heterozygotes), and on
none of the alleles (uncharacterized group).Table 2 Tel Hashomer key to severity score [9]
Points
Age of onset
< 5 years 3
5–10 years 2
10–20 years 1
> 20 years 0
Frequency of attacks
> 2 per month 3
1–2 per month 2
< 1 per month 1











Total of points indicates the following: mild disease, 2–5 points; moderate
disease, 6–10 points; severe disease, >10 points.Urine analysis were also collected to detect the presence
of any abnormalities especially proteinuria or hematuria.
Ethical considerations
The aim and nature of the study was explained for each
candidate and/or parent before inclusion. An informed
written consent was obtained from parents/surrogates
before enrollment. Children old enough were asked for
consent.
Statistical analysis
Data were statistically described in terms of range, mean ±
standard deviation (± SD), median, frequencies (number
of cases) and percentages when appropriate. Comparison
of numerical variables between the study groups was
done using Kruskal Wallis test with Mann Whitney U
test for independent samples as posthoc multiple 2-
group comparisons. For comparing categorical data, Chi
square (χ2) test was performed. Exact test was used in-
stead when the expected frequency is less than 5. p values
less than 0.05 was considered statistically significant. All
statistical calculations were done using computer pro-
grams Microsoft Excel 2007 (Microsoft Corporation, NY,
USA) and SPSS (Statistical Package for the Social Sci-
ence; SPSS Inc., Chicago, IL, USA) version 15 for Micro-
soft Windows.
Results
Patients were classified according to mutations and allele
status into 3 groups: group 1 (homozygous group)
included 20 patients (28.6%) of whom 12 were males
and 8 were females (M:F = 1.5:1), group 2 (heterozygous
group) included 40 patients (57.1%) of whom 21 were
males and 19 were females (M:F = 1.1:1) and group 3
(uncharacterized patients) included 10 patients (14.3%)
of whom 7 were males and 3 were females (M:F = 2.3:1).
The mean age of onset and mean age at diagnosis of
all study population, were 4.86 ± 2.56, and 7.14 ± 2.89
years respectively. The mean time interval between
disease onset and diagnosis was 2.31 ± 1.57 years ran-
ging from 0.6 – 7 years. The duration of follow-up
period was ranging from 1–11 years with a mean of
2.75 ± 2.35 years.
Comparing patients’ characteristics, the mean age at
diagnosis was significantly higher in heterozygous than
Figure 1 Clinical profile of the different study groups.
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follow-up was significantly lower in the heterozygous
patients (P=0.03). However, no statistically significant
differences were detected between heterozygous and the
uncharacterized group regarding the above mentioned
parameters. Moreover, none of the above mentioned
parameters were statistically significant when comparing
patients’ characteristics, consanguinity and family history
rates of all study groups (Table 3).
As regards the clinical features of all patients; fever
was the most common presenting feature in 95.7% of
cases (67 out of 70 patients), abdominal pain was a con-
stant feature in both homozygotes and uncharacterized
groups and was documented in all patients of the two
groups. Arthritis was a common feature in both hetero-
zygotes and the uncharacterized group and was docu-
mented in 87.5% (35/40), and 90% (9/10) of patients
respectively. Proteinuria was detected in 6 patients
(8.6%) in whom renal biopsy was indicated. Amyloidosis
was detected in only one heterozygous case; diagnosis
was based on the result of renal biopsy (Figure 1).
Regarding response to colchicine therapy, it was
complete in 16/70 (22.9%), incomplete in 52/70 (74.3%)
and no response in (2.9%). Although incomplete re-
sponse was documented in a significant proportion of
patients, the mean number of attacks per year was sig-
nificantly lower after treatment (4.51 ± 4.82, range=0 -
24) than before initiation of therapy (24.09 ± 10.02,
range=10-72); P=0.00.
Table 4 shows that the disease severity score was mod-
erate in all of the uncharacterized patients (100%). The
mild to moderate disease severity score was noted in a
significant proportion of heterozygous and gene-negative
groups than homozygous group (P=0.01). Also patients’
response to colchicine therapy was significantly better in
the heterozygous group (P=0.023). Moreover, the mean
colchicine dose that was required to control the attacksTable 3 Comparison between patients’ characteristics, consan
Item Heterozygo
Age of onset (yeas), mean ± SD 5.20 ± 2.51
Age at diagnosis (years), mean ± SD 7.81 ± 2.79
Time interval between disease onset and diagnosis (years)
Mean ± SD 2.63 ± 1.63
Median (range) 2 (1–6)
Duration of follow-up (years), mean ± SD 2.18 ± 1.41
Median (range) 1.75 (1–6)
Male/Female 21/19
Consanguinity (n%) 14 (35%)
Family history of FMF (n%) 7 (17.5%)
Family history of amyloidosis (n%) 4 (10%)
FMF= familial Mediterranean fever.
*P-value less than 0.05 is considered statistically significant.was lower in the heterozygous group than homozygous
and gene –ve groups and that difference was statistically
significant (P=0.04).
Figure 2 demonstrates the major genotypes in both
heterozygous and homozygous groups. As shown,
E148Q, V726A, and M680I mutations were the most
common mutations seen in the heterozygous group and
were found in 11/40 patients (27.5%), 8/40 patients
(20%), and 6/40 patients (15%) respectively. Homozygos-
ity for M680I, M694V, and M694I were found in 5/20
patients (25%), 4/20 patients (20%), and 4/20 patients
(20%) respectively.
In the homozygous group, out of 20 patients, diseases
associated with FMF were documented in 4 patients
(20%); Henoch-schonlein purpura (HSP) in one patient
(5%) with M694V-wild type mutation, inflammatory
bowel disease (IBD) in two patients (10%) with M694V
and M680I mutations, SLE (systemic lupus erythemato-
sus) in one patient (5%) with M680I mutation. Regarding
the heterozygous group, out of 40 patients, diseasesguinity and family history rate of the three groups
us (n=40) Homozygous (n=20) Gene-ve (n=10) P-value
4.32 ± 2.58 4.63 ± 2.76 0.35
6.01 ± 2.75 6.76 ± 3.08 0.07
1.75 ± 1.03 2.15 ± 1.94 0.13
1.8 (1–4) 1.3 (1–7)
3.80 ± 3.24 2.95 ± 2.77 0.11
2 (1–11) 1.95 (1 – 9)
12/8 7/3 0.58
11 (55%) 1 (10%) 0.05
7 (35%) 0 (0%) 0.06
0 (0%) 0 (0%) 0.20
Table 4 Comparison between disease severity score, response to colchicine therapy, and number of attacks per year in
the three study groups
Item Hetero-zygous (n=40) Homo-zygous (n=20) Gene-ve (n=10) P-value
Disease severity score, n (%) Mild 9 (22.5) 0 (0.0) 0 (0.0) 0.01*
Moderate 26 (65.5) 14 (70) 10 (100)
Severe 5 (12.5) 6 (30) 0 (0.0)
Response to colchicine, n (%) Complete 13 (32.5) 1 (5.0) 2 (20) 0.09
Incomplete 25 (62.5) 19 (95.0) 8 (80)
No response 2 (5) 0 (0.0) 0 (0.0)
Colchicine dose to control attacks, mean ± SD 1.26 ± 0.36 1.47 ± 0.34 1.40 ± 0.21 0.04*
Number of attacks per year, mean ± SD Before treatment (range) 23.70 ± 11.47 (10–72) 24.40 ± 6.95 (12–36) 25 ± 9.76 (16–48) 0.6
After treatment (range) 4.80 ± 5.81 (0–24) 3.95 ± 2.50 (0–10) 4.5 ± 4.22 (0–12) 0.9
*P-value less than 0.05 is considered statistically significant.
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(22.5%); HSP in two patients (5%) with E148Q and
M680I mutation, IBD in one patients (2.5%) with V726A
mutation, JRA (juvenile rheumatoid arthritis) in three
patients (7.5%) with E148Q, M680I and M694V-V726A
mutations, SLE in two patients (5.0%) with V726A and
E148Q mutations, Rheumatic fever in one patient (2.5%)
with M694V mutation. Regarding mortality rate, none of
our patients had died during the period of the study.Discussion
FMF is an autoinflammatory disease common in eastern
Mediterranean populations. It is characterized by febrile
episodes of serosal and synovial inflammation causing
marked increase in the acute phase response [11]. FMF
is more prevalent in males, with a male to female ratio
of 1.5-2:1 [12].
In the current study, a male preponderance was noted
in all the study population, with an overall M:F ratio of
1.3:1. Male to female ratios of 1.5:1, 1.1:1, and 2.3:1 were
reported among homozygotes, heterozygotes, and theFigure 2 Major genotypes in heterozygous and homozygous
groups.uncharacterized group respectively. A male preponder-
ance was noted in different other studies. El-Garf et al.
[13], who studied 136 Egyptian patients in the period be-
tween January, 2005 and July, 2008 recruited from the
rheumatology clinic, Pediatric Hospital, Cairo University,
as well as three referral centers (a general rheumatology,
pediatric rheumatology and general pediatric clinics),
also reported a M:F ratio of 1.9:1. Similarly, Settin et al.
[14], who studied 66 Egyptian patients who were re-
ferred from various hospitals to Genetics Department,
Mansoura University, Children’s Hospital for confirm-
ation of diagnosis through molecular analysis also
reported a M:F ratio of 1.3:1. Another retrospective
study done by Booty et al. [15] reported that out of 28
FMF patients with only one identified MEFV mutation,
and who were seen at the National Institutes of Health,
Bethesda MD - USA, 15 were males and 13 were females
with M:F ratio of 1.15:1.
However, Duşunsel et al. [16] who reviewed the med-
ical records of 102 Turkish patients, documented a M:F
ratio of 1:1.3 (a slight female preponderance), but these
results are not statistically significant and do not support
the suggestion that FMF may have incomplete pene-
trance in female subjects [17]. Although a male predom-
inance among FMF patients has been documented in
several ethnic groups, most studies have reported that
FMF affects both genders in a similar ratio [18,19].
The onset of clinical manifestations in FMF occurs be-
fore 5 years of age in 63–68% of cases and before 20
years of age in 90% of cases. The onset may be as early
as 6 months of age [20]. In our study, the mean age of
onset, mean age at diagnosis, and mean time interval be-
tween disease onset and diagnosis of all study popula-
tion, were 4.86 ± 2.56, 7.14 ± 2.89, and 2.31 ± 1.57 years
respectively. The mean age at diagnosis was signific-
antly higher in heterozygous group than homozygous
group and the mean duration of follow-up was signifi-
cantly lower in the heterozygous patients. Our study
populations had age of onset much earlier than reported.
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ried out on 415 clinically diagnosed FMF Turkish
patients; the mean age of onset was 13.9 ± 9.8 years.
Duşunsel et al. [16] also reported a mean age of onset, a
mean age at diagnosis, and a median time interval be-
tween disease onset and diagnosis of 6.8 ± 3.7, 9.7 ± 3.7
and 2 (0.5–11) years respectively. This earlier age of
onset that was observed in our study may be explained
by the early detection of FMF patients in our rheumatol-
ogy pediatric unit by clinical suspicion before confirm-
ation by genetic analysis.
FMF is considered as an autosomal recessive heredi-
tary disease, associated with a single gene named MEFV
[22]. However, about one-third of FMF patients bear a
single mutation on one allele, suggesting that the disease
might be transferred as an autosomal dominant trait
with partial penetration. Alternatively, an additional
gene—yet to be identified—might be responsible for the
disease in these cases with single allele mutation [23].
The inherited pattern of FMF which is mostly reces-
sive was supported on the basis of consanguinity and
positive family history. Regarding consanguinity of the
study population; 37.14% of patients had consanguin-
eous parents, all of them were homozygotes and hetero-
zygotes except one patient who was gene-negative. A
positive family history of FMF was recorded in 14
patients (20%), of whom 7 patients were homozygotes
and 7 patients were heterozygotes. Family history of
amyloidosis was noted in 4 patients (5.7%) all of them
were heterozygous. Consanguinity in our study is nearly
similar to Duşunsel et al. [16] who reported that 30.4%
of their patients had consanguineous parents, a positive
family history of FMF was recorded in 26.5% of patients
and a family history of amyloidosis was noted in 5.9% of
patients. El-Garf et al. [13] reported that, out of their
136 patients, a positive consanguinity was present in 32
(23.5%) patients and a positive family history in 45
(33.1%) patients. Settin et al. [14] showed that 21.2% of
their patients had a positive family history for FMF;
however parental consanguinity was positive in 63.3% of
these cases which was more than that in our results.
These differences may due to familial predisposition of
FMF in certain populations and the impact of cultural
traditions.
Regarding clinical presentations among our study
groups; fever was a prevalent feature in all groups, and
was documented in 90%, 97.5%, and 100% of homo-
zygtes, heterozygotes, and the uncharacterized group re-
spectively. Abdominal pain was a constant feature in
both homozygotes and the uncharacterized group and
was documented in all patients. Arthritis was a common
feature in both heterozygotes and the uncharacterized
group and was documented in 87.5%, and 90% of
patients respectively. Variation in clinical picture of FMFpatients with positive gene mutation was in agreement
with many reports but differ from each other in the fre-
quency of each clinical picture; this difference may be
due to the difference in racial group and geographic re-
gion, and may be due to the difference in predominant
gene mutation in different populations (phenotype geno-
type correlation) [24,25].
Based on the Tel Hashomer Severity Score [10], sever-
ity score of the disease was calculated. The mean sever-
ity score was 8.27 ± 2.03. Mild to moderate disease
severity scores were detected in a significantly higher
proportion of heterozygotes and the uncharacterized
group than homozygotes.
Attacks of FMF can be prevented by prophylactic col-
chicine (0.02-0.03 mg/kg/day; maximum: 2 mg/day) in 1
to 2 divided doses. Colchicine therapy reduces the fre-
quency of acute attacks, but also greatly decreases the
probability of development of amyloidosis; it may pro-
duce partial regression of existing amyloidosis [20]. In
our study all patients received colchicine therapy (dose
0.5 - 2 mg/day); only 22.9% of them showed complete
response, 74.3% showed incomplete response and 2.9%
showed no response. Although incomplete response to
colchicine was documented in a significant proportion
of patients, the mean number of attacks per year was
significantly lower after treatment than before initiation
of therapy. Colchicine dose needed to control attacks
was significantly lower in heterozygotes than homozy-
gotes. Also response to colchicine therapy was signifi-
cantly better in the heterozygous group. Contrary to our
results, Al-Wahdneh and Dahabreh [26] reported that
prescribing colchicine to all of their patients, in doses
ranged between 0.5 mg and 2 mg daily according to age
and response, resulted in disappearance of the attacks
completely in 68% of cases, a significant decrease in the
number and severity of attacks in 29% and no response
to treatment in 3% of patients. Similarly, Duşunsel et al.
[16] reported that 77.5% of their patients had complete
response, 13.7% had some attacks despite colchicine,
and 2% were unresponsive. Booty et al. [15] also
reported that among their 28 heterozygous patients, in-
formation on colchicine responsiveness was unavailable
for 3 patients, colchicine response was either complete
or partial in 84% of patients (21/25), and 4 patients did
not respond at all. Fourteen patients (56%) had a
complete response, while 7 patients (28%) had periodic
attacks of inflammation although less frequently while
on treatment. The reasons for lacking response to col-
chicine could be explained by knowing the fact that
colchicine has to go through several stages on its way
to controlling inflammation, therefore its efficacy may
be affected at various points. Theoretically, problems
with its absorption in the intestine can change the
therapeutic plasma levels. Problems with the functioning
Talaat et al. Italian Journal of Pediatrics 2012, 38:66 Page 7 of 8
http://www.ijponline.net/content/38/1/66of the human multidrug resistance (MDR1 gene) (P-
glycoprotein pump) in white blood cells or serous
membrane cells can also affect colchicine function
[27,28]. Modulation of colchicine metabolism by differ-
ent factors (erythromycin, clarithromycyn, lovastatin,
simvastatin, cyclosporin, grapefruit juice, etc.) at the
level of cytochrome 3A4 can also influence the effect of
colchicine [29].
In our study, out of 70 patients, 5 patients (7.1%)
underwent surgery; appendectomy was performed in 4
patients and herniotomy was done in only one patient.
Our results are nearly similar to Al-Wahadneh and
Dahabreh [26] who reported that only 2 out of 56
patients (3.7%) underwent appendectomy. Duşunsel
et al. [16] also reported that 4 out of 102 patients (3.4%)
underwent surgery, and all of them had appendectomy.
Settin et al., [14] reported a higher percent of patients
who underwent surgery; 15 out of 66 patients (22.7%)
underwent laparotomy during severe abdominal pain ei-
ther for exploration or for appendectomy. This high per-
cent could be a result of the severe abdominal pain that
forced the patients to be bed ridden and that was docu-
mented in 66.7% of their patients.
In our study, the most frequent mutations in all
patients were E148Q, M680I, and V726A and were
detected in 20%, 15.7%, and 14.3% of patients respect-
ively. In an Egyptian study, among 66 patients, M694V
was the most common allelic mutation found followed
by V726A then M680I (18.8%, 17.42% 12.1% respect-
ively) [14]. In another Egyptian study, among 136
patients, it was found that the most frequent gene muta-
tions were V726A, M694V, M680I, E148Q and M694I in
41.2, 32.4, 29.4, 25 and 20.6% of patients respectively
[13]. This differences in the allelic mutations found
among patients could indicate the mutational heterogen-
eity of FMF in the Egyptian population. This mutational
heterogeneity appears to be less obvious among other
ethnic populations. M694V mutation was found in 97%
of the North African Jews in Israel [30], while M694I
mutation was present in 80% of Algerian Arabs [31]. In
the studies by Touitou et al. [6], and by the Turkish
FMF study group [11], the most common MEFV muta-
tion in Turkey is M694V (57.0 and 51.4%, respectively),
followed by M680I (16.5 and 14.4%, respectively), and
V726A (13.9 and 8.6%, respectively). Possible explan-
ation is that having only one MEFV mutation may give
rise to a FMF phenotype in the presence of one or more
modifying alleles in other related genes, or other envir-
onmental factors like a stress. Asymptomatic carriers for
one FMF mutation have biochemical evidence for sub-
clinical inflammation [7,32] and a more recent study
found a higher frequency of carriers for highly pene-
trant FMF mutations among patients with systemic in-
flammatory response syndrome (SIRS) and sepsis [33].Therefore, modifying alleles could contribute to an in-
flammation dosage threshold, which is necessary to de-
velop systemic inflammation and symptomatic FMF.
HSP and polyarteritis nodosa (PAN) are more com-
mon in FMF patients than in the general population
[19]. In our study, HSP was determined in 4.3% of
patients and this in agreement with a high prevalence of
vasculitis found in FMF patients but PAN was not
found. Duşunsel et al. [16] also reported HSP in 6.8% of
their patients.Conclusion and recommendations
We confirm that in the current study of 70 patients with
FMF; fever, abdominal pain and arthritis were the most
common presenting features for homozygous, heterozy-
gous and uncharacterized patients. E148Q, V726A, and
M680I were the most common mutations detected in
the heterozygous group. Homozygosity were found for
M680I, M694V, and M694I mutations in 13 patients
(65% of homozygotes). The mean colchicine dose
required to control the attacks was significantly lower
and patients’ response to colchicine therapy was signifi-
cantly better in the heterozygous group than homozy-
gous group.
Wide indications for genotyping based on expanded
clinical profile led to more frequent diagnosis of FMF.
Concerning heterozygotes presenting with severe pheno-
type, they should be further analyzed for less common
second MEFV mutation using gene sequencing. Even
the 10 uncharacterized patients with positive FMF cri-
teria -according to Tel Hashomer criteria for diagnosis
of FMF- who had no identified mutations, the following
explanations could account for this observation; we
screened only for 12 set of genes despite of presence of
160 gene mutation update. Secondly, unknown mutation
may exist. Thirdly another as-yet-unidentified FMF locus
may exist. So, despite the current knowledge regarding
FMF, prospective clinical studies with large numbers of
patients and different ethnic groups will help to better
clarify this considerable disease.
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